Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Ghezzi

Showing results (21-30 of 133) with videos related to

Pageof 14
Sort By:
Human Brain Mapping|December 25, 2008
Is a preserved functional reserve a mechanism limiting clinical impairment in pediatric MS patients?Maria A Rocca, Martina Absinta, Angelo Ghezzi, et al.
The Lancet. Neurology|August 22, 2014
Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and researchAmy Waldman, Angelo Ghezzi, Amit Bar-Or, et al.
Neurology and Therapy|May 14, 2026
Pediatric Radiologically Isolated Syndrome (RIS): A Case with Active Disease 18 Years LaterAngelo Ghezzi, Mattia Pozzato, Pietro Annovazzi, et al.
Neurology and Therapy|February 27, 2026
The Use of Patient-Reported Outcome Measures in Developmental Age: A Complementary Tool for Pediatric Multiple Sclerosis PrognosisPaola Zaratin, Maria Pia Amato, Giampaolo Brichetto, et al.
Neurology and Therapy|February 16, 2020
Correction to: Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMSII TrialsAngelo Ghezzi, Tanuja Chitnis, Annik K-Laflamme, et al.
Journal of Neurology|June 10, 2008
A 3-year diffusion tensor MRI study of grey matter damage progression during the earliest clinical stage of MSMarco Rovaris, Elda Judica, Antonia Ceccarelli, et al.
Neurology and Therapy|July 21, 2019
Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II TrialsAngelo Ghezzi, Tanuja Chitnis, Annik K-Laflamme, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 30, 2019
Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMSAngelo Ghezzi, Giancarlo Comi, Luigi Maria Grimaldi, et al.
Journal of the Neurological Sciences|July 28, 2014
Uhthoff's phenomena and brain MRI suggesting demyelinating lesions: RIS or CIS? A case reportDamiano Baroncini, Mauro Zaffaroni, Giorgio Minonzio, et al.
Lancet (London, England)|May 4, 2002
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)Luca Durelli, Elisabetta Verdun, Pierangelo Barbero, et al.
Pageof 14

Showing results (21-30 of 133) with videos related to

Sort By:
Pageof 14
Human Brain Mapping|December 25, 2008
Is a preserved functional reserve a mechanism limiting clinical impairment in pediatric MS patients?Maria A Rocca, Martina Absinta, Angelo Ghezzi, et al.
The Lancet. Neurology|August 22, 2014
Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and researchAmy Waldman, Angelo Ghezzi, Amit Bar-Or, et al.
Neurology and Therapy|May 14, 2026
Pediatric Radiologically Isolated Syndrome (RIS): A Case with Active Disease 18 Years LaterAngelo Ghezzi, Mattia Pozzato, Pietro Annovazzi, et al.
Neurology and Therapy|February 27, 2026
The Use of Patient-Reported Outcome Measures in Developmental Age: A Complementary Tool for Pediatric Multiple Sclerosis PrognosisPaola Zaratin, Maria Pia Amato, Giampaolo Brichetto, et al.
Neurology and Therapy|February 16, 2020
Correction to: Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMSII TrialsAngelo Ghezzi, Tanuja Chitnis, Annik K-Laflamme, et al.
Journal of Neurology|June 10, 2008
A 3-year diffusion tensor MRI study of grey matter damage progression during the earliest clinical stage of MSMarco Rovaris, Elda Judica, Antonia Ceccarelli, et al.
Neurology and Therapy|July 21, 2019
Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II TrialsAngelo Ghezzi, Tanuja Chitnis, Annik K-Laflamme, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 30, 2019
Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMSAngelo Ghezzi, Giancarlo Comi, Luigi Maria Grimaldi, et al.
Journal of the Neurological Sciences|July 28, 2014
Uhthoff's phenomena and brain MRI suggesting demyelinating lesions: RIS or CIS? A case reportDamiano Baroncini, Mauro Zaffaroni, Giorgio Minonzio, et al.
Lancet (London, England)|May 4, 2002
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)Luca Durelli, Elisabetta Verdun, Pierangelo Barbero, et al.
Pageof 14